SIRION Biotech was founded with the goal of developing a new generation of viral vector technologies for gene and cell therapy and vaccine development. SIRION produces novel therapeutic viral vectors and utilises proprietary technology platforms based on lenti-, adeno- and adeno-associated viruses to accelerate the progress of its partners in drug development.
The technology is already being used in over 40 clinical trials. The first market approval was granted in 2019. In 2021, the Munich-based start-up was taken over by Perkin Elmer, a US corporation. SIRION has facilities in Munich, Heidelberg, Paris und Boston.
"We were very impressed by SIRION’s technical and market expertise from the beginning and actively supported the company from an early stage."
said Roman Huber, former Managing Director of Bayern Kapital